Impact of ECOG performance status on recurrent/metastatic head and neck squamous cell carcinomas treated with anti-PD1 inhibitors.

Cameron Chalker,Vicky Wu,Jenna M. Voutsinas,Victoria Hwang,Christina S. Baik,J.J. Liao,Sylvia Lee,Neal D. Futran,Jeffrey J. Houlton,Brittany Barber,Upendra Parvathaneni,George E. Laramore,Rafael Santana-Davila,Keith D. Eaton,Renato G. Martins,Cristina P. Rodriguez

Impact of ECOG performance status on recurrent/metastatic head and neck squamous cell carcinomas treated with anti-PD1 inhibitors.

2021

Cameron Chalker
Vicky Wu
Jenna M. Voutsinas
Victoria Hwang
Christina S. Baik
J.J. Liao
Sylvia Lee
Neal D. Futran
Jeffrey J. Houlton
Brittany Barber
Upendra Parvathaneni
George E. Laramore
Rafael Santana-Davila
Keith D. Eaton
Renato G. Martins
Cristina P. Rodriguez

e18004Background: Anti-PD1 checkpoint inhibitors (ICI) represent an established standard of care for patients with recurrent/metastatic head & neck squamous cell carcinoma (RMHNSCC). Landmark studi...

Keywords:

Internal medicine
Cell
Medicine
ECOG Performance Status
Oncology
standard of care
anti pd1
head and neck
basal cell
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations